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Sir 
We are pleased to see this editorial continuing the discussion on this key treatment question for 
these fractures. We write to address the concerns expressed by Ghert and McKee on the design, 
conduct and reporting of PROFHER in relation to the study population.1 
Foremost, we wish to correct the misapprehension that surgeons participating in the PROFHER trial 
were placed in a quandary as to the inclusion of fracture dislocations. As shown in Table I of our 
article in this journal,2 these together with clear indications for surgery (“such as severe soft-tissue 
compromise requiring surgery/emergency treatment (nerve injury/dysfunction)”) were explicitly 
excluded from our study population. In compliance with CONSORT reporting standards, we reported 
on the numbers who were ineligible and therefore excluded for each category in the participant flow 
diagram.1 Given journal word limit, it is inevitable that some information appeared “in the fine 
print”. 
As observed in the editorial, the number of four-part fractures identified in the independent 
classification was low but, as discussed in our article, the numbers of fractures perceived by 
surgeons to be four-part is likely to have been higher.2 Our subgroup analyses for fracture severity 
based on tuberosity involvement and the Neer classification did not suggest any trend of differential 
treatment response for more complex fractures.1 
Regarding the representativeness of the population at individual centres, given the relatively low 
proportions of PROFHER participants recruited in some centres, the impact of any selective local 
recruitment practices will have been at least partly mitigated by the inclusion of many diverse 
recruiting sites with a large number of recruiting surgeons. We never expected the number of trial 
participants recruited to include all cases seen in clinical practice given the trial’s exclusion criteria 
and the patient consent rate. We have described and discussed the representativeness of the whole 
trial population elsewhere,1,2 and we believe that the PROFHER participants are representative of 
those cases for which true uncertainty regarding surgical or non-surgical treatment existed. From an 
analytical perspective, the relatively small number of patients per surgeon and recruiting site have 
minimised the influence of such clustering on the trial outcomes, as shown by our sensitivity analysis 
testing of this aspect.1 We hope that the above allays the concerns relating to PROFHER raised in the 
editorial. 
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